AEON BIOPHARMA INC (AEON)

US00791X1000 - Common Stock

1.04 +0.04 (+4.42%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates

		2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030
Revenue YoY % growth			-100.00%				N/A
EBITDA YoY % growth			100.00%	N/A	N/A	13K	N/A
EBIT YoY % growth			100.00%	-1.936M	-3.326M -71.78%	-86K 97.41%	N/A -113,509.02%
Operating Margin			N/A	N/A	N/A	N/A	N/A
EPS YoY % growth			N/A	N/A	N/A	N/A	N/A 161.54%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates

	Q2 / 24	Q3 / 24	Q4 / 24	Q1 / 25	Q2 / 25	Q3 / 25	Q4 / 25
EPS Q2Q % growth
Revenue Q2Q % growth
EBITDA Q2Q % growth
EBIT Q2Q % growth

All data in USD

Recent Earnings VS Estimates Surprises (USD)

Period	Reported	Estimate	Difference	Surprise
Q1 2024 Q2Q % growth	-0.28	-0.32	0.04	11.45%
Q4 2023 Q2Q % growth	-0.71	-0.41	-0.30	-74.02%
Q3 2023 Q2Q % growth	1.15	-0.54	1.69	312.73%
Q4 2022 Q2Q % growth
Q3 2022 Q2Q % growth
Q2 2022 Q2Q % growth
Q1 2022 Q2Q % growth
Q2 2021 Q2Q % growth
Q4 2020 Q2Q % growth
Q2 2020 Q2Q % growth

Recent Revenue VS Estimates Surprises (USD)

Period	Reported	Estimate	Difference	Surprise
Q4 2022 Q2Q % growth
Q3 2022 Q2Q % growth
Q2 2022 Q2Q % growth
Q1 2022 Q2Q % growth
Q2 2021 Q2Q % growth
Q4 2020 Q2Q % growth
Q2 2020 Q2Q % growth

EPS and Revenue Revisions

	Next Q (1 month)	Next Q (3 month)	Next Year (1 month)	Next Year (3 month)
EPS	0%	0%	146.75%	146.75%
Revenue	N/A	N/A	N/A	N/A